| Teniposide (VM-26) and carboplatin as initial therapy for small cell lung cancer. | |
| | |
MedLine Citation:
|
PMID: 1329228 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Forty-four patients with previously untreated histologically proven small cell lung cancer (SCLC) were treated with a combination of teniposide 60 mg/m2 intravenously (IV) on days 1 through 5 and carboplatin 400 mg/m2 IV on day 1 every 28 days for six courses. Patients with limited disease (LD) subsequently received prophylactic cranial and thoracic radiotherapy. Of the 44 patients, 40 were evaluable for response: 31 (78%) achieved an objective response; 9 of 18 patients (50%) with LD had a complete response (CR), with a partial response (PR) plus CR rate of 78%. Two of 22 patients (9%) with extensive disease achieved a CR, with a combined PR and CR rate of 77%. Median duration of response for all evaluable patients was 253 days (36 weeks). Median duration of survival for LD patients was 368 days (52 weeks). Survival of LD patients was 86% at 6 months, 52% at 12 months, and 26% at 18 months. Median duration of survival for all patients in the study was 275 days, with a survival of 79% at 6 months, 36% at 1 year, and 12% at 18 months. Myelosuppression was the main toxicity, with World Health Organization (WHO) grade 3 or 4 infection occurring in 38% of patients. However, no patient died of sepsis or hemorrhage. Treatment was otherwise well tolerated, with no neurotoxicity or nephrotoxicity documented. The high activity of this drug combination justifies its use as first-line treatment of previously untreated SCLC. |
| | |
Authors:
|
G D Goss; M Vincent; R Corringham; C Germond; C Sinoff; G Kane; J Rowen; S Corringham; H Dhaliwal |
Related Documents
:
|
9708628 - Small-cell lung carcinoma: an analysis of 194 consecutive patients. 16314638 - Role of chemotherapy and the receptor tyrosine kinases kit, pdgfralpha, pdgfrbeta, and ... 16462498 - Examining time intervals between diagnosis and treatment in the management of patients ... 12635088 - Prophylactic cranial irradiation in small cell lung cancer. 12909218 - Oropharyngeal candidiasis caused by non-albicans yeast in patients receiving external b... 18021278 - Analysis of renal cell carcinoma with subdiaphragmatic macroscopic venous invasion (t3b). |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study |
Journal Detail:
|
Title: Seminars in oncology Volume: 19 ISSN: 0093-7754 ISO Abbreviation: Semin. Oncol. Publication Date: 1992 Apr |
Date Detail:
|
Created Date: 1992-10-26 Completed Date: 1992-10-26 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 0420432 Medline TA: Semin Oncol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 69-74 Citation Subset: IM |
Affiliation:
|
Northeastern Ontario Regional Cancer Centre, Ontario Cancer Treatment and Research Foundation, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Alopecia / chemically induced Antineoplastic Combined Chemotherapy Protocols / administration & dosage, adverse effects, therapeutic use* Carboplatin / administration & dosage*, adverse effects Carcinoma, Small Cell / drug therapy* Female Humans Infusions, Intravenous Lung Neoplasms / drug therapy* Male Middle Aged Neutropenia / chemically induced Remission Induction Survival Rate Teniposide / administration & dosage*, adverse effects Thrombocytopenia / chemically induced |
| Chemical | |
Reg. No./Substance:
|
29767-20-2/Teniposide; 41575-94-4/Carboplatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Teniposide in the treatment of small cell lung cancer: a review.
Next Document: Teniposide alone and in combination chemotherapy in small cell lung cancer.